825 related articles for article (PubMed ID: 17953285)
1. [High-dose CEF (cyclophosphamide, epirubicin, fluorouracil) as primary chemotherapy in locally advanced breast cancer: long-term results].
Conti F; Carpano S; Sergi D; Di Lauro L; Amodio A; Vici P; Abbate MI; Ferranti FR; Viola G; Botti C; Foggi P; Sperduti I; Lopez M
Clin Ter; 2007; 158(4):331-41. PubMed ID: 17953285
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial.
Veyret C; Levy C; Chollet P; Merrouche Y; Roche H; Kerbrat P; Fumoleau P; Fargeot P; Clavere P; Chevallier B
Cancer; 2006 Dec; 107(11):2535-44. PubMed ID: 17054108
[TBL] [Abstract][Full Text] [Related]
3. Multimodality treatment of 128 patients with locally advanced breast carcinoma in the era of mammography screening using standard polychemotherapy with 5-fluorouracil, epirubicin, and cyclophosphamide: prognostic and therapeutic implications.
Karlsson YA; Malmström PO; Hatschek T; Fornander TG; Söderberg M; Bengtsson NO; Jansson TE; Sjöberg SM; Bergh JC
Cancer; 1998 Sep; 83(5):936-47. PubMed ID: 9731898
[TBL] [Abstract][Full Text] [Related]
4. Multidisciplinary therapy of locally far-advanced or inflammatory breast cancer with fixed perioperative sequence of epirubicin, vinorelbine, and Fluorouracil chemotherapy, surgery, and radiotherapy: long-term results.
Ardavanis A; Scorilas A; Tryfonopoulos D; Orphanos G; Missitzis I; Karamouzis M; Chrysochoou M; Sotiropoulou A; Arnogiannaki N; Ioannidis G; Pissakas G; Rigatos G
Oncologist; 2006 Jun; 11(6):563-73. PubMed ID: 16794236
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy and concomitant irradiation in inflammatory breast cancer.
Tubiana-Mathieu N; Lejeune C; Bonnier P; Genet D; Adjadj DJ; Berda JF; Muracciole X; Delaby F; Clavere P; Benyoub A; Rhein B; Juin B; Piana L
Anticancer Res; 2001; 21(4B):3061-7. PubMed ID: 11712811
[TBL] [Abstract][Full Text] [Related]
6. Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer.
Honkoop AH; Luykx-de Bakker SA; Hoekman K; Meyer S; Meyer OW; van Groeningen CJ; van Diest PJ; Boven E; van der Wall E; Giaccone G; Wagstaff J; Pinedo HM
Oncologist; 1999; 4(2):106-11. PubMed ID: 10337380
[TBL] [Abstract][Full Text] [Related]
7. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial.
Bonneterre J; Roché H; Kerbrat P; Brémond A; Fumoleau P; Namer M; Goudier MJ; Schraub S; Fargeot P; Chapelle-Marcillac I
J Clin Oncol; 2005 Apr; 23(12):2686-93. PubMed ID: 15837983
[TBL] [Abstract][Full Text] [Related]
8. [Locally advanced non inflammatory breast cancer treated by combined chemotherapy and preoperative irradiation: updated results in a series of 120 patients].
Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J
Cancer Radiother; 2004 Jun; 8(3):155-67. PubMed ID: 15217583
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial comparing neo-adjuvant versus adjuvant chemotherapy in operable locally advanced breast cancer (T4b N0-2 M0).
Deo SV; Bhutani M; Shukla NK; Raina V; Rath GK; Purkayasth J
J Surg Oncol; 2003 Dec; 84(4):192-7. PubMed ID: 14756429
[TBL] [Abstract][Full Text] [Related]
10. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95.
; Basser RL; O'Neill A; Martinelli G; Green MD; Peccatori F; Cinieri S; Coates AS; Gelber RD; Aebi S; Castiglione-Gertsch M; Viale G; Price KN; Goldhirsch A
J Clin Oncol; 2006 Jan; 24(3):370-8. PubMed ID: 16421418
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy.
Low JA; Berman AW; Steinberg SM; Danforth DN; Lippman ME; Swain SM
J Clin Oncol; 2004 Oct; 22(20):4067-74. PubMed ID: 15483018
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
13. A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results.
Rouëssé J; de la Lande B; Bertheault-Cvitkovic F; Serin D; Graïc Y; Combe M; Leduc B; Lucas V; Demange L; Nguyen TD; Castèra D; Krzisch C; Villet R; Mouret-Fourme E; Garbay JR; Noguès C;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1072-80. PubMed ID: 16504757
[TBL] [Abstract][Full Text] [Related]
14. Epidoxorubicin and paclitaxel as primary chemotherapy for T > 3 cm and T4 breast cancer patients.
Bellino R; Cortese P; Danese S; De Sanctis C; Durando A; Genta F; Grio R; Giardina G; Katsaros D; Massobrio M; Richiardi G; Vicelli R
Anticancer Res; 2000; 20(6C):4825-8. PubMed ID: 11205227
[TBL] [Abstract][Full Text] [Related]
15. Combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer: updated results in a series of 120 patients.
Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1062-73. PubMed ID: 15234040
[TBL] [Abstract][Full Text] [Related]
16. Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide.
Papaldo P; Lopez M; Cortesi E; Cammilluzzi E; Antimi M; Terzoli E; Lepidini G; Vici P; Barone C; Ferretti G; Di Cosimo S; Nistico C; Carlini P; Conti F; Di Lauro L; Botti C; Vitucci C; Fabi A; Giannarelli D; Marolla P
J Clin Oncol; 2003 Sep; 21(18):3462-8. PubMed ID: 12972521
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan.
Kimura M; Tominaga T; Takatsuka Y; Toi M; Abe R; Koyama H; Takashima S; Nomura Y; Miura S; Kimijima I; Tashiro H; Ohashi Y;
Breast Cancer; 2010 Jul; 17(3):190-8. PubMed ID: 19575284
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.
Levine MN; Pritchard KI; Bramwell VH; Shepherd LE; Tu D; Paul N;
J Clin Oncol; 2005 Aug; 23(22):5166-70. PubMed ID: 16051958
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes.
Battelli N; Massacesi C; Braconi C; Pilone A; Manzione L; Dinota A; Cobelli S; Scanni A; Sturba F; Giacomini G; Morale D; Giorgi F; Tummarello D; Cascinu S
Am J Clin Oncol; 2006 Aug; 29(4):380-4. PubMed ID: 16891866
[TBL] [Abstract][Full Text] [Related]
20. Dose- intensified, preoperative and adjuvant chemotherapy in patients with T3- and T4- breast cancer: toxicity, clinical and pathological remission.
Blohmer JU; Paepke S; Kissner L; Elling D; Fleige B; Grineisen Y; Lichtenegger W
Zentralbl Gynakol; 1999; 121(11):522-5. PubMed ID: 10612219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
